Factors associated with high placebo response in clinical studies of hot flashes: a meta-analysis

被引:7
作者
Miyazaki, Kentaro [1 ,2 ]
Kaneko, Masayuki [3 ]
Narukawa, Mamoru [1 ]
机构
[1] Kitasato Univ, Grad Sch Pharmaceut Sci, Dept Clin Med Pharmaceut Med, Tokyo, Japan
[2] Astellas Pharma Inc, Tokyo, Japan
[3] Showa Univ, Sch Pharmaceut Sci, Dept Hosp Pharmaceut, Tokyo, Japan
来源
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2022年 / 29卷 / 02期
关键词
Hot flashes; Meta-analysis; Placebo; QUALITY-OF-LIFE; MENOPAUSAL VASOMOTOR SYMPTOMS; BREAST-CANCER SURVIVORS; LOW-DOSE ESTRADIOL; DOUBLE-BLIND; PERIMENOPAUSAL WOMEN; CONTROLLED TRIAL; EFFICACY; MULTICENTER; MODERATE;
D O I
10.1097/GME.0000000000001895
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Importance: High placebo response can often mask the evaluation of active treatment in clinical studies for women with hot flashes and potentially undermine the evaluation of new treatments. Objective: The aim of this meta-analysis was to determine the factors associated with high placebo response (defined as the reduction in the mean number of hot flash frequency from baseline) in randomized, controlled, double-blind studies enrolling women with hot flashes. Evidence Review: To identify eligible studies, Embase, MEDLINE, and BIOSIS Previews were searched for English-language articles published between April 1975 and August 2020. Placebo-controlled, double-blind, randomized studies that assessed changes in hot flash frequency were included if they satisfied the defined criteria. We conducted univariate and multivariate analyses using categorical and numerical data. Categorical data included the following variables and levels in brackets: active treatment type (hormone therapy /non- hormone therapy / complementary and alternative medicine), administration route (oral/non-oral), study region (in/excluded the US), breast cancer population (in/excluded), entry criteria of hot flash severity (moderate to severe only/all included), parallel or crossover study, placebo run-in period before treatment (yes/no), and menopausal status (postmenopausal only/include perimenopausal/include premenopausal). Numerical data included published year, pretreatment period duration, treatment period duration, number of sites, number of total participants, number of placebo participants, number of treatment arms, mean age, BMI, and hot flash frequency at baseline. Findings: Forty-three of the 802 identified publications were included in the review. Multivariate analysis identified three individual factors associated with high placebo response: treatment period duration, number of treatment arms, and BMI. Conclusions and Relevance: We identified several factors associated with high placebo response in clinical studies of women with hot flashes. Knowing these factors may enable proactive implementation of operational and analytic strategies that further aid in determining the true treatment effect of an intervention.
引用
收藏
页码:239 / 246
页数:8
相关论文
共 59 条
[41]   Bupropion for Control of Hot Flashes in Breast Cancer Survivors: A Prospective, Double-Blind, Randomized, Crossover, Pilot Phase II Trial [J].
Nunez, Geila Ribeiro ;
Pinczowski, Helio ;
Zanellato, Rebecca ;
Tateyama, Livia ;
Schindler, Fernanda ;
Fonseca, Fernando ;
del Giglio, Auro .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2013, 45 (06) :969-979
[42]   Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial [J].
Pandya, KJ ;
Morrow, GR ;
Roscoe, JA ;
Zhao, HW ;
Hickok, JT ;
Pajon, E ;
Sweeney, TJ ;
Banerjee, TK ;
Flynn, PJ .
LANCET, 2005, 366 (9488) :818-824
[43]   The 2017 hormone therapy position statement of The North American Menopause Society [J].
Pinkerton, JoAnn V. ;
Aguirre, Fernando Sanchez ;
Blake, Jennifer ;
Cosman, Felicia ;
Hodis, Howard ;
Hoffstetter, Susan ;
Kaunitz, Andrew M. ;
Kingsberg, Sheryl A. ;
Maki, Pauline M. ;
Manson, JoAnn E. ;
Marchbanks, Polly ;
McClung, Michael R. ;
Nachtigall, Lila E. ;
Nelson, Lawrence M. ;
Pace, Diane Todd ;
Reid, Robert L. ;
Sarrel, Phillip M. ;
Shifren, Jan L. ;
Stuenkel, Cynthia A. ;
Utian, Wulf H. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2017, 24 (07) :728-753
[44]  
Pinkerton JV, 2014, MENOPAUSE, V21, P567, DOI [10.1097/GME.0b013e3182a7c073, 10.1097/gme.0b013e3182a7c073]
[45]   Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial [J].
Pinkerton, JoAnn V. ;
Constantine, Ginger ;
Hwang, Eunhee ;
Cheng, Ru-fong J. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (01) :28-37
[46]   Effect of Vitamin E Supplementation on Plasma Nitric Oxide in Menopausal Women with Hot Flashes: A Cross-Over, Randomized Clinical Trial [J].
Rezasoltani, Parvaneh ;
Elliyoun, Nahid ;
Ziaie, Tahereh ;
Leyli, Ehsan Kazemnezhad ;
Aski, Soudabeh Kazemi ;
Sobhani, Abdolrasoul .
IRANIAN RED CRESCENT MEDICAL JOURNAL, 2018, 20 (09)
[47]   Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause [J].
Sarri, G. ;
Pedder, H. ;
Dias, S. ;
Guo, Y. ;
Lumsden, M. A. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2017, 124 (10) :1514-1523
[48]  
Shobeiri Fatemeh, 2016, J Menopausal Med, V22, P14, DOI 10.6118/jmm.2016.22.1.14
[49]   Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms [J].
Simon, JA .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2006, 13 (02) :222-231
[50]   Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial [J].
Simon, James A. ;
Gaines, Tatiana ;
LaGuardia, Katherine D. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2016, 23 (11) :1214-1221